Open AccessClinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States
Author(s) -
Lucia Millham,
Justine A Scott,
Paul E. Sax,
Fatma M. Shebl,
Krishna P. Reddy,
Elena Losina,
Rochelle P. Walensky,
Kenneth A. Freedberg
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002241
Subject(s) - medicine , cost effectiveness , cohort , regimen , cost effectiveness analysis , quality adjusted life year , incremental cost effectiveness ratio , cost–benefit analysis , human immunodeficiency virus (hiv) , demography , family medicine , ecology , risk analysis (engineering) , biology , sociology
We projected the clinical outcomes, cost-effectiveness, and budget impact of ibalizumab plus an optimized background regimen (OBR) for people with multidrug-resistant (MDR) HIV in the United States.